Patient Selection for Allogeneic Hematopoietic Cell Transplantation (HCT): the Evolution of HCT Risk Assessment

被引：3
作者：
Muffly, Lori [1 ]
机构：
[1] Stanford Univ, Div Blood & Marrow Transplantat, Stanford, CA USA
来源：
CURRENT HEMATOLOGIC MALIGNANCY REPORTS | 2015年 / 10卷 / 01期
关键词：
Hematopoietic cell transplantation (HCT); Allogeneic; Transplant methodologies; Non-relapse mortality (NRM); VERSUS-HOST-DISEASE; ACUTE MYELOID-LEUKEMIA; MINIMAL RESIDUAL DISEASE; PRETRANSPLANTATION SERUM FERRITIN; C-REACTIVE PROTEIN; COMORBIDITY INDEX; OLDER PATIENTS; GERIATRIC ASSESSMENT; HEMATOLOGIC MALIGNANCIES; MARROW TRANSPLANTATION;
D O I：
10.1007/s11899-014-0241-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The use of allogeneic hematopoietic cell transplantation is expanding, with disproportionate growth witnessed in older adults with hematologic malignancies. As the chronological age barrier to transplant fades, refining the pre-hematopoietic cell transplantation (HCT) risk assessment to better capture host health status and disease characteristics is essential. This review summarizes recent efforts to move the field forward towards achieving this goal. Many of these risk assessment tools are currently included in prospective clinical trials; routine clinical use requires greater understanding of how to best incorporate this new information into HCT decision making.
引用
收藏
页码：28 / 34
页数：7
相关论文
共 48 条
  • [1] Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?
    Alousi, Amin M.
    Le-Rademacher, Jennifer
    Saliba, Rima M.
    Appelbaum, Frederick R.
    Artz, Andrew
    Benjamin, Jonathan
    Devine, Steven M.
    Kan, Fangyu
    Laughlin, Mary J.
    Lazarus, Hillard M.
    Liesveld, Jane
    Perales, Miguel-Angel
    Maziarz, Richard T.
    Sabloff, Mitchell
    Waller, Edmund K.
    Eapen, Mary
    Champlin, Richard E.
    [J]. BLOOD, 2013, 121 (13) : 2567 - 2573
  • [2] Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia
    Appelbaum, Frederick R.
    [J]. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2013, 26 (03) : 279 - 284
  • [3] Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation
    Armand, Philippe
    Kim, Haesook T.
    Cutler, Corey S.
    Ho, Vincent T.
    Koreth, John
    Alyea, Edwin P.
    Soiffer, Robert J.
    Antin, Joseph H.
    [J]. BLOOD, 2007, 109 (10) : 4586 - 4588
  • [4] Iron Overload in Allogeneic Hematopoietic Cell Transplantation Outcome: A Meta-Analysis
    Armand, Philippe
    Kim, Haesook T.
    Virtanen, Johanna M.
    Parkkola, Riitta K.
    Itala-Remes, Maija A.
    Majhail, Navneet S.
    Burns, Linda J.
    DeFor, Todd
    Trottier, Bryan
    Platzbecker, Uwe
    Antin, Joseph H.
    Wermke, Martin
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (08) : 1248 - 1251
  • [5] Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation
    Armand, Philippe
    Kim, Haesook T.
    Logan, Brent R.
    Wang, Zhiwei
    Alyea, Edwin P.
    Kalaycio, Matt E.
    Maziarz, Richard T.
    Antin, Joseph H.
    Soiffer, Robert J.
    Weisdorf, Daniel J.
    Rizzo, J. Douglas
    Horowitz, Mary M.
    Saber, Wael
    [J]. BLOOD, 2014, 123 (23) : 3664 - 3671
  • [6] A disease risk index for patients undergoing allogeneic stem cell transplantation
    Armand, Philippe
    Gibson, Christopher J.
    Cutler, Corey
    Ho, Vincent T.
    Koreth, John
    Alyea, Edwin P.
    Ritz, Jerome
    Sorror, Mohamed L.
    Lee, Stephanie J.
    Deeg, H. Joachim
    Storer, Barry E.
    Appelbaum, Frederick R.
    Antin, Joseph H.
    Soiffer, Robert J.
    Kim, Haesook T.
    [J]. BLOOD, 2012, 120 (04) : 905 - 913
  • [7] Pretreatment C-Reactive Protein Is a Predictor for Outcomes after Reduced-intensity Allogeneic Hematopoietic Cell Transplantation
    Artz, Andrew S.
    Wickrema, Amittha
    Dinner, Shira
    Godley, Lucy A.
    Kocherginsky, Masha
    Odenike, Olatoyosi
    Rich, Elizabeth S.
    Stock, Wendy
    Ulaszek, Jodie
    Larson, Richard A.
    van Besien, Koen
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (11) : 1209 - 1216
  • [8] Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation
    Artz, Andrew S.
    Pollyea, Daniel A.
    Kocherginsky, Masha
    Stock, Wendy
    Rich, Elizabeth
    Odenike, Olatoyosi
    Zimmerman, Todd
    Smith, Sonali
    Godley, Lucy
    Thirman, Michael
    Daugherty, Christopher
    Extermann, Martine
    Larson, Richard
    van Besien, Koen
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (09) : 954 - 964
  • [9] Prognostic Value of Minimal Residual Disease Quantification Before Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia: The ALL-REZ BFM Study Group
    Bader, Peter
    Kreyenberg, Hermann
    Henze, Guenter H. R.
    Eckert, Cornelia
    Reising, Miriam
    Willasch, Andre
    Barth, Andrea
    Borkhardt, Arndt
    Peters, Christina
    Handgretinger, Rupert
    Sykora, Karl-Walter
    Holter, Wolfgang
    Kabisch, Hartmut
    Klingebiel, Thomas
    von Stackelberg, Arend
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (03) : 377 - 384
  • [10] Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation Score Allows a Better Stratification of High-Risk Patients Undergoing Reduced-Toxicity Allogeneic Hematopoietic Cell Transplantation
    Barba, Pere
    Martino, Rodrigo
    Antonio Perez-Simon, Jose
    Fernandez-Aviles, Francesc
    Castillo, Nerea
    Luis Pinana, Jose
    Lopez-Anglada, Lucia
    Rovira, Montserrat
    Bosch, Francesc
    Carreras, Enric
    Lopez Corral, Lucia
    Sierra, Jorge
    Valcarcel, David
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (01) : 66 - 72
12345